|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:dateCreated |
2008-6-26
|
|
pubmed:abstractText |
Epidemiologic studies have suggested that hypertriglyceridemia and insulin resistance are related to the development of colon cancer. Nuclear peroxisome proliferator-activated receptors (PPAR), which play a central role in lipid and glucose metabolism, had been hypothesized as being involved in colon cancerogenesis. In animal studies the lipid-lowering PPAR ligand bezafibrate suppressed colonic tumors. However, the effect of bezafibrate on colon cancer development in humans is unknown. Therefore, we proposed to investigate a possible preventive effect of bezafibrate on the development of colon cancer in patients with coronary artery disease during a 6-year follow-up.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/18565233-10393723,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18565233-10691680,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18565233-10880410,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18565233-10965515,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18565233-11161410,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18565233-11216866,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18565233-11284737,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18565233-11289109,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18565233-11459852,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18565233-11535544,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18565233-11694656,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18565233-11927499,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18565233-12782154,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18565233-12834541,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18565233-12946210,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18565233-14522940,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18565233-15123532,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18565233-15456334,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18565233-15516843,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18565233-15764152,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18565233-15892897,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18565233-16168052,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18565233-16435997,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18565233-16489531,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18565233-16534881,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18565233-16574099,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18565233-16606335,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18565233-17071576,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18565233-17264754,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18565233-17307056,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18565233-17893232,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18565233-17978568,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18565233-7749056,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18565233-7881343,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18565233-9839735
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1475-2840
|
|
pubmed:author |
pubmed-author:AdlerYehudaY,
pubmed-author:BeharSolomonS,
pubmed-author:BoykoValentinaV,
pubmed-author:FeinbergMicha SMS,
pubmed-author:FismanEnrique ZEZ,
pubmed-author:GoldenbergIlanI,
pubmed-author:MotroMichaelM,
pubmed-author:SchwammenthalEhudE,
pubmed-author:ShemeshJosephJ,
pubmed-author:TanneDavidD,
pubmed-author:TenenbaumAlexanderA
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
7
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
18
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:18565233-Aged,
pubmed-meshheading:18565233-Bezafibrate,
pubmed-meshheading:18565233-Colonic Neoplasms,
pubmed-meshheading:18565233-Coronary Artery Disease,
pubmed-meshheading:18565233-Dose-Response Relationship, Drug,
pubmed-meshheading:18565233-Female,
pubmed-meshheading:18565233-Follow-Up Studies,
pubmed-meshheading:18565233-Humans,
pubmed-meshheading:18565233-Hypolipidemic Agents,
pubmed-meshheading:18565233-Incidence,
pubmed-meshheading:18565233-Kaplan-Meier Estimate,
pubmed-meshheading:18565233-Ligands,
pubmed-meshheading:18565233-Longitudinal Studies,
pubmed-meshheading:18565233-Male,
pubmed-meshheading:18565233-Middle Aged,
pubmed-meshheading:18565233-Multivariate Analysis,
pubmed-meshheading:18565233-Peroxisome Proliferator-Activated Receptors,
pubmed-meshheading:18565233-Randomized Controlled Trials as Topic
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Does the lipid-lowering peroxisome proliferator-activated receptors ligand bezafibrate prevent colon cancer in patients with coronary artery disease?
|
|
pubmed:affiliation |
Cardiac Rehabilitation Institute, Chaim Sheba Medical Center, Tel-Hashomer, affiliated with Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel. altenen@post.tau.ac.il
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
